Allopregnanolone modulates striatal dopamingergic activity of rats under different gonadal hormones conditions.
OBJECTIVE
Progesterone modulates dopamine (DA) release in corpus striatum. Our objective was to evaluate the effect of the i.c.v injection of the neurosteroid allopregnanolone (ALL), a progesterone metabolite on dopaminergic activity in the corpus striatum of rats under different gonadal hormonal conditions.


METHODS
We have measured the concentrations of DOPA, DA and DOPAC (main metabolite of DA) in the corpus striatum in estrus and diestrus rats and in ovariectomized rats without hormonal replacement (OVX group) and primed with estrogen and progesterone (OVX(i) group). Additionally, we have used the aromatic acid decarboxylase inhibitor NSD in order to evaluate the function of tyrosine hydroxylase (TH), the rate-limiting enzyme of dopamine synthesis.


RESULTS
ALL significantly decreased the striatal concentrations of both DA and DOPAC in the estrus. On the other hand, ALL increased significantly the levels of DA in the OVX(i) group. The DOPA accumulation in OVX(i) after NSD treatment in the ALL-treated groups was greater than in the vehicle group. However, the estrus group did not modify the DOPA accumulation after NSD injection.


CONCLUSIONS
Our results suggest that ALL could modulate the dopaminergic transmission in the corpus striatum by causing changes in the activity of TH and/or in the pre- and post-synaptic dopaminergic terminals in the corpus striatum. This neurosteroidal mechanism could be a new kind of neurotransmitter systems modulation accomplished on TH activity itself and/or on the second messengers not related to ionic channels. Additionally, our results reinforce the idea of a close relationship between the fast non-genomic mechanism of ALL and the genomic actions of estrogen and progesterone.
Laconi
M R
MR
Laboratorio de Investigaciones Neuroquímicas, Comportamentales y Endócrinas (LINCE-IMBECU-CONICET) and Area de Farmacología, Mendoza, Argentina.
Reggiani
P C
PC
Penissi
A
A
Yunes
R
R
Cabrera
R J
RJ
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000704:Analysis of Variance; D000777:Anesthetics; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects*; D004295:Dihydroxyphenylalanine / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D030762:Estrous Cycle; D005260:Female; D042341:Gonadal Hormones / Q000502:physiology*; D009043:Motor Activity / Q000187:drug effects; D010052:Ovariectomy / Q000379:methods; D011280:Pregnanolone / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D000777:Anesthetics; D042341:Gonadal Hormones; D015102:3,4-Dihydroxyphenylacetic Acid; D004295:Dihydroxyphenylalanine; D011280:Pregnanolone; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine